Camille J Devereux (Camille Devereux)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 5

Top Topics

High Fat Diet Induced

Hydrogen Peroxide

Insulin Resistance

Top Venues

American journal of physiology. Endocrinology and metabolism

Science translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Camille J Devereux, Jacqueline Bayliss, Stacey N Keenan, Magdalene K Montgomery, Matthew J Watt
Investigating dual inhibition of ACC and CD36 for the treatment of nonalcoholic fatty liver disease in mice. American journal of physiology. Endocrinology and metabolism 324 (2) (2023)
Camille J Devereux, Jacqueline Bayliss, Stacey N Keenan, Magdalene K Montgomery, Matthew J Watt
Investigating dual inhibition of ACC and CD36 for the treatment of nonalcoholic fatty liver disease in mice. American journal of physiology. Endocrinology and metabolism 324 (2) (2023)
Camille J Devereux, Jacqueline Bayliss, Stacey N Keenan, Magdalene K Montgomery, Matthew J Watt
Investigating dual inhibition of ACC and CD36 for the treatment of nonalcoholic fatty liver disease in mice. American journal of physiology. Endocrinology and metabolism 324 (2) (2023)
Camille J Devereux, Jacqueline Bayliss, Stacey N Keenan, Magdalene K Montgomery, Matthew J Watt
Investigating dual inhibition of ACC and CD36 for the treatment of nonalcoholic fatty liver disease in mice. American journal of physiology. Endocrinology and metabolism 324 (2) (2023)
Magdalene K Montgomery, Jacqueline Bayliss, Camille J Devereux, Ayenachew Bezawork-Geleta, David Roberts, Cheng Huang, Ralf Bernd Schittenhelm, Andrew Ryan, Scott L Townley, Luke A Selth, Trevor J Biden, Gregory R Steinberg, Dorit Samocha-Bonet, Ruth C R Meex, Matthew J Watt
SMOC1 is a glucose-responsive hepatokine and therapeutic target for glycemic control. Science translational medicine 12 (559) (2021)